Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Navidea Biopharma (NAVB) Reports Q2 Loss of $0.24
August 8, 2019 5:35 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.24), versus ($0.29) reported last year. Revenue for the quarter came in at $260.09 million, versus $542.13 million reported last year.
Second Quarter 2019 Highlights and Subsequent Events
Effected a one-for-twenty reverse stock split and received notification of stock price compliance from the NYSE AmericanAnnounced that results of the Companys NAV3-21 clinical study for diagnosis of rheumatoid arthritis were presented at the... More